- Home
- BLRX vs IMNN Comparison
BLRX vs IMNN Comparison
Compare BLRX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- IMNN
- Stock Information
- Founded
- BLRX 2003
- IMNN 1982
- Country
- BLRX Israel
- IMNN United States
- Employees
- BLRX N/A
- IMNN N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- IMNN Health Care
- Exchange
- BLRX Nasdaq
- IMNN Nasdaq
- Market Cap
- BLRX 12.2M
- IMNN 13.6M
- IPO Year
- BLRX 2011
- IMNN 1985
- Fundamental
- Price
- BLRX $3.10
- IMNN $1.05
- Analyst Decision
- BLRX Buy
- IMNN Strong Buy
- Analyst Count
- BLRX 2
- IMNN 2
- Target Price
- BLRX $26.00
- IMNN $21.50
- AVG Volume (30 Days)
- BLRX 26.4K
- IMNN 123.6K
- Earning Date
- BLRX 05-27-2025
- IMNN 05-12-2025
- Dividend Yield
- BLRX N/A
- IMNN N/A
- EPS Growth
- BLRX N/A
- IMNN N/A
- EPS
- BLRX N/A
- IMNN N/A
- Revenue
- BLRX $28,940,000.00
- IMNN N/A
- Revenue This Year
- BLRX N/A
- IMNN N/A
- Revenue Next Year
- BLRX N/A
- IMNN N/A
- P/E Ratio
- BLRX N/A
- IMNN N/A
- Revenue Growth
- BLRX 502.92
- IMNN N/A
- 52 Week Low
- BLRX $2.85
- IMNN $0.64
- 52 Week High
- BLRX $35.60
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- BLRX 41.70
- IMNN 59.05
- Support Level
- BLRX $3.01
- IMNN $1.01
- Resistance Level
- BLRX $3.61
- IMNN $1.18
- Average True Range (ATR)
- BLRX 0.22
- IMNN 0.08
- MACD
- BLRX 0.02
- IMNN 0.01
- Stochastic Oscillator
- BLRX 32.89
- IMNN 60.61
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About IMNN Imunon Inc.
Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.